CD8A and neoplasm: The dual‐cell membrane‐coated SPNE served as a nanovaccine, which increased the mature DCs ratio from 34.1% to 65.1% (Figure 9f) and the population of activated CD8+ T cells 2.87‐folds in lymph nodes, in comparison with those in the PBS group (Figure 9g). The treatment induced strong memory immune responses that the population of CD45+CD3+CD62L+CD44+ T cells was five times higher than other groups (Figure 9h), effectively preventing tumor recurrence within 30 days.